Chronic obstructive pulmonary disease (COPD) is a global health problem, and since 2001,
the Global Initiative for Chronic Obstructive Lung Disease (GOLD) has published its strategy …

Background: The proportion of people in the United States who are members of at least two
ethnic groups is projected to increase to 10% by the year 2050. This makes addressing …

Background We evaluated the effect of dual, longacting inhaled bronchodilator treatment on
exacerbations in patients with severe and very severe chronic obstructive pulmonary …

Background Inhaled corticosteroids (ICS) are anti‐inflammatory drugs that have proven
benefits for people with worsening symptoms of chronic obstructive pulmonary disease …

Chronic obstructive pulmonary disease (COPD) remains a major public health problem. It is
the fourth leading cause of chronic morbidity and mortality in the United States, and is …

Background The role of inhaled corticosteroids (ICS) in chronic obstructive pulmonary
disease (COPD) has been the subject of much controversy. Major international guidelines …

Chronic obstructive pulmonary disease (COPD) is a progressive and debilitating respiratory
condition that leads to significant burden, both medically and financially. It affects millions of …

The American Thoracic Society/European Respiratory Society jointly created a Task Force
on “Outcomes for COPD pharmacological trials: from lung function to biomarkers” to inform …

Rationale: Exacerbations are key drivers of morbidity and mortality in chronic obstructive
pulmonary disease (COPD). Objectives: We compared the relative efficacy of the long-acting …

Background Increased oxidative stress and inflammation has a role in the pathogenesis of
chronic obstructive pulmonary disease (COPD). Drugs with antioxidant and anti …